1. Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010–2017
- Author
-
Erwan Drezen, Monica Dinulescu, Catherine Droitcourt, André Happe, Marc Pracht, Philippe Tuppin, Florence Poizeau, Anne Thuret, Sandrine Kerbrat, Frédéric Balusson, Bernard Guillot, Lise Boussemart, Alain Dupuy, Emmanuel Oger, Caroline Rault, Thierry Lesimple, Recherche en Pharmaco-épidémiologie et Recours aux Soins (REPERES), Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP), Pharmaco-Épidémiologie des Produits de Santé (PEPS), CHU Pontchaillou [Rennes], Caisse nationale d'assurance maladie des travailleurs salariés [CNAMTS], Hôpital Lapeyronie [Montpellier] (CHU), Santé publique France - French National Public Health Agency [Saint-Maurice, France], Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Eugène Marquis (CRLCC), Agence Nationale de Sécurité du Médicament, Chard-Hutchinson, Xavier, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )
- Subjects
Male ,0301 basic medicine ,Oncology ,Skin Neoplasms ,Time Factors ,Databases, Factual ,[SDV]Life Sciences [q-bio] ,Immune checkpoint inhibitors ,medicine.medical_treatment ,Biochemistry ,law.invention ,Targeted therapy ,0302 clinical medicine ,Randomized controlled trial ,law ,Antineoplastic Combined Chemotherapy Protocols ,Medicine ,Immune Checkpoint Inhibitors ,Melanoma ,Aged, 80 and over ,Middle Aged ,Cytotoxic chemotherapy ,3. Good health ,[SDV] Life Sciences [q-bio] ,Treatment Outcome ,030220 oncology & carcinogenesis ,Female ,France ,medicine.medical_specialty ,Metastatic melanoma ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Dermatology ,03 medical and health sciences ,[SDV.CAN] Life Sciences [q-bio]/Cancer ,Internal medicine ,Overall survival ,Humans ,Mortality ,Protein Kinase Inhibitors ,Molecular Biology ,Aged ,business.industry ,Cell Biology ,Survival Analysis ,Clinical trial ,030104 developmental biology ,National health insurance ,business ,Administrative Claims, Healthcare ,Follow-Up Studies - Abstract
Immune checkpoint inhibitors and targeted therapies have profoundly altered the management of several cancers over the past decade. Metastatic melanoma has been at the forefront of these changes. We provide here a nationwide overview and an assessment of changes in survival in France. We included 10,936 patients receiving a systemic treatment for metastatic cutaneous melanoma between 2010 and 2017 using the French National Health Insurance database (Système National des Données de Santé). Over the study period, there was a doubling of the number of new patients receiving a systemic treatment. Cytotoxic chemotherapy was progressively replaced by targeted therapy and immune checkpoint inhibitors. Patients having initiated a first-line treatment since June 2015 gained 46% overall survival compared with those initiating treatment before 2012. Overall survival at 24 months rose from 21% to 44%. We provide real-world evidence for the improvement of overall survival in the past decade among patients with metastatic melanoma. Although the characteristics of the patients treated can vary across periods, this type of exhaustive real-world data provides evidence from broader populations than those included in clinical trials.
- Published
- 2021
- Full Text
- View/download PDF